OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
A Systematic Review of Cost-Effectiveness of Sodium-Glucose Cotransporter Inhibitors for Type 2 Diabetes
Yilin Yoshida, Xi Cheng, Hui Shao, et al.
Current Diabetes Reports (2020) Vol. 20, Iss. 4
Closed Access | Times Cited: 30
Yilin Yoshida, Xi Cheng, Hui Shao, et al.
Current Diabetes Reports (2020) Vol. 20, Iss. 4
Closed Access | Times Cited: 30
Showing 1-25 of 30 citing articles:
2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines
Salim S. Virani, L. Kristin Newby, Suzanne V. Arnold, et al.
Circulation (2023) Vol. 148, Iss. 9
Open Access | Times Cited: 587
Salim S. Virani, L. Kristin Newby, Suzanne V. Arnold, et al.
Circulation (2023) Vol. 148, Iss. 9
Open Access | Times Cited: 587
Association of Race/Ethnicity, Gender, and Socioeconomic Status With Sodium-Glucose Cotransporter 2 Inhibitor Use Among Patients With Diabetes in the US
Lauren A. Eberly, Lin Yang, Nwamaka D. Eneanya, et al.
JAMA Network Open (2021) Vol. 4, Iss. 4, pp. e216139-e216139
Open Access | Times Cited: 259
Lauren A. Eberly, Lin Yang, Nwamaka D. Eneanya, et al.
JAMA Network Open (2021) Vol. 4, Iss. 4, pp. e216139-e216139
Open Access | Times Cited: 259
2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease
Salim S. Virani, L. Kristin Newby, Suzanne V. Arnold, et al.
Journal of the American College of Cardiology (2023) Vol. 82, Iss. 9, pp. 833-955
Open Access | Times Cited: 217
Salim S. Virani, L. Kristin Newby, Suzanne V. Arnold, et al.
Journal of the American College of Cardiology (2023) Vol. 82, Iss. 9, pp. 833-955
Open Access | Times Cited: 217
SGLT2 Inhibitors – The New Standard of Care for Cardiovascular, Renal and Metabolic Protection in Type 2 Diabetes: A Narrative Review
Samuel Seidu, Vicki Alabraba, Sarah Davies, et al.
Diabetes Therapy (2024) Vol. 15, Iss. 5, pp. 1099-1124
Open Access | Times Cited: 8
Samuel Seidu, Vicki Alabraba, Sarah Davies, et al.
Diabetes Therapy (2024) Vol. 15, Iss. 5, pp. 1099-1124
Open Access | Times Cited: 8
Cost-Effectiveness of Newer Antidiabetic Drugs as Second-Line Treatment for Type 2 Diabetes: A Systematic Review
Jiejin Zhu, Ying Zhou, Qingyu Li, et al.
Advances in Therapy (2023) Vol. 40, Iss. 10, pp. 4216-4235
Open Access | Times Cited: 12
Jiejin Zhu, Ying Zhou, Qingyu Li, et al.
Advances in Therapy (2023) Vol. 40, Iss. 10, pp. 4216-4235
Open Access | Times Cited: 12
Update in non-alcoholic fatty liver disease management: role of sodium-glucose cotransporter 2 inhibitors
Oscar René Zambrano-Vásquez, Fernando Cortés-Camacho, Jorge Ismael Castañeda‐Sánchez, et al.
Life Sciences (2025), pp. 123638-123638
Closed Access
Oscar René Zambrano-Vásquez, Fernando Cortés-Camacho, Jorge Ismael Castañeda‐Sánchez, et al.
Life Sciences (2025), pp. 123638-123638
Closed Access
Estimating the value of sodium‐glucose cotransporter‐2 inhibitors within the context of contemporary guidelines and the totality of evidence
Phil McEwan, V. Foos, Becky Martin, et al.
Diabetes Obesity and Metabolism (2023) Vol. 25, Iss. 7, pp. 1830-1838
Open Access | Times Cited: 10
Phil McEwan, V. Foos, Becky Martin, et al.
Diabetes Obesity and Metabolism (2023) Vol. 25, Iss. 7, pp. 1830-1838
Open Access | Times Cited: 10
Challenges and Strategies in Implementing Novel Kidney Protective and Cardioprotective Therapies in Patients With Diabetes and Kidney Disease
Christine P. Limonte, Julio A. Lamprea‐Montealegre, Katherine R. Tuttle
Seminars in Nephrology (2024) Vol. 44, Iss. 2, pp. 151520-151520
Closed Access | Times Cited: 3
Christine P. Limonte, Julio A. Lamprea‐Montealegre, Katherine R. Tuttle
Seminars in Nephrology (2024) Vol. 44, Iss. 2, pp. 151520-151520
Closed Access | Times Cited: 3
Cost-Effectiveness of SGLT2 Inhibitors in a Real-World Population: A MICADO Model-Based Analysis Using Routine Data from a GP Registry
Xinyu Li, Rudolf T. Hoogenveen, Mohamed El Alili, et al.
PharmacoEconomics (2023) Vol. 41, Iss. 10, pp. 1249-1262
Open Access | Times Cited: 8
Xinyu Li, Rudolf T. Hoogenveen, Mohamed El Alili, et al.
PharmacoEconomics (2023) Vol. 41, Iss. 10, pp. 1249-1262
Open Access | Times Cited: 8
Thirty-Day and 90-Day Episode of Care Spending Following Heart Failure Hospitalization Among Medicare Beneficiaries
Samuel W. Reinhardt, Katherine Clark, Xin Xin, et al.
Circulation Cardiovascular Quality and Outcomes (2022) Vol. 15, Iss. 7
Open Access | Times Cited: 13
Samuel W. Reinhardt, Katherine Clark, Xin Xin, et al.
Circulation Cardiovascular Quality and Outcomes (2022) Vol. 15, Iss. 7
Open Access | Times Cited: 13
Comparing the effectiveness and cost-effectiveness of sulfonylureas and newer diabetes drugs as second-line therapy for patients with type 2 diabetes
Matteo Franchi, Giacomo Pellegrini, Angelo Avogaro, et al.
BMJ Open Diabetes Research & Care (2024) Vol. 12, Iss. 3, pp. e003991-e003991
Open Access | Times Cited: 2
Matteo Franchi, Giacomo Pellegrini, Angelo Avogaro, et al.
BMJ Open Diabetes Research & Care (2024) Vol. 12, Iss. 3, pp. e003991-e003991
Open Access | Times Cited: 2
SGLT-2 Inhibitors on Top of Current Pharmacological Treatments for Heart Failure: A Comparative Review on Outcomes and Cost Effectiveness
Ilaria Cavallari, Ernesto Maddaloni, Annunziata Nusca, et al.
American Journal of Cardiovascular Drugs (2021) Vol. 22, Iss. 3, pp. 263-270
Closed Access | Times Cited: 13
Ilaria Cavallari, Ernesto Maddaloni, Annunziata Nusca, et al.
American Journal of Cardiovascular Drugs (2021) Vol. 22, Iss. 3, pp. 263-270
Closed Access | Times Cited: 13
SGLT2 Inhibitors Are Associated With Reduced Cardiovascular Disease in Patients With Type 2 Diabetes
Wendy Wang, Lin Y. Chen, Rob F. Walker, et al.
Mayo Clinic Proceedings (2023) Vol. 98, Iss. 7, pp. 985-996
Closed Access | Times Cited: 4
Wendy Wang, Lin Y. Chen, Rob F. Walker, et al.
Mayo Clinic Proceedings (2023) Vol. 98, Iss. 7, pp. 985-996
Closed Access | Times Cited: 4
A Systematic Review of Cost-Effectiveness Studies of Newer Non-Insulin Antidiabetic Drugs: Trends in Decision-Analytical Models for Modelling of Type 2 Diabetes Mellitus
Henrik Vitus Bering Laursen, Emmelie Ploug Jørgensen, Peter Vestergaard, et al.
PharmacoEconomics (2023) Vol. 41, Iss. 11, pp. 1469-1514
Open Access | Times Cited: 4
Henrik Vitus Bering Laursen, Emmelie Ploug Jørgensen, Peter Vestergaard, et al.
PharmacoEconomics (2023) Vol. 41, Iss. 11, pp. 1469-1514
Open Access | Times Cited: 4
Current gaps in management and timely referral of cardiorenal complications among people with type 2 diabetes mellitus in the Middle East and African countries: Expert recommendations
Alper Sönmez, Hani Sabbour, Akram Echtay, et al.
Journal of Diabetes (2022) Vol. 14, Iss. 5, pp. 315-333
Open Access | Times Cited: 7
Alper Sönmez, Hani Sabbour, Akram Echtay, et al.
Journal of Diabetes (2022) Vol. 14, Iss. 5, pp. 315-333
Open Access | Times Cited: 7
Systematic Review of the Economic Evaluation of Sodium–Glucose Cotransporter-2 Inhibitors Used as Treatment in Patients with Heart Failure
Kyung-ae Nam, D. Cho, Hyun-Ji Kim, et al.
Clinical Drug Investigation (2023) Vol. 43, Iss. 7, pp. 463-474
Closed Access | Times Cited: 3
Kyung-ae Nam, D. Cho, Hyun-Ji Kim, et al.
Clinical Drug Investigation (2023) Vol. 43, Iss. 7, pp. 463-474
Closed Access | Times Cited: 3
Pharmacoeconomic evaluation of dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus: a systematic literature review
Zhen Ruan, Huimin Zou, Qing Lei, et al.
Expert Review of Pharmacoeconomics & Outcomes Research (2022) Vol. 22, Iss. 4, pp. 555-574
Closed Access | Times Cited: 4
Zhen Ruan, Huimin Zou, Qing Lei, et al.
Expert Review of Pharmacoeconomics & Outcomes Research (2022) Vol. 22, Iss. 4, pp. 555-574
Closed Access | Times Cited: 4
Healthcare resource utilization after initiation of sodium‐glucose co‐transporter‐2 inhibitors versus dipeptidyl peptidase‐4 inhibitors or other glucose‐lowering drugs in Japanese patients with type 2 diabetes
Shun Kohsaka, M. Takeda, Yoko Kidani, et al.
Diabetes Obesity and Metabolism (2021) Vol. 23, Iss. S2, pp. 28-39
Open Access | Times Cited: 5
Shun Kohsaka, M. Takeda, Yoko Kidani, et al.
Diabetes Obesity and Metabolism (2021) Vol. 23, Iss. S2, pp. 28-39
Open Access | Times Cited: 5
Dapagliflozin Versus Sacubitril–Valsartan to Improve Outcomes of Patients with Reduced Ejection Fraction and Diabetes Mellitus
Ariel Hammerman, Joseph Azuri, Enis Aboalhasan, et al.
American Journal of Cardiovascular Drugs (2021) Vol. 22, Iss. 3, pp. 325-331
Closed Access | Times Cited: 4
Ariel Hammerman, Joseph Azuri, Enis Aboalhasan, et al.
American Journal of Cardiovascular Drugs (2021) Vol. 22, Iss. 3, pp. 325-331
Closed Access | Times Cited: 4
Informing and Empowering Patients and Clinicians to Make Evidence-Supported Outcome-Based Decisions in Relation to SGLT2 Inhibitor Therapies: The Use of the Novel Years of Drug administration (YoDa) Concept
Lakshminarayanan Varadhan, Ponnusamy Saravanan, Sarah Ali, et al.
Clinical Drug Investigation (2022) Vol. 42, Iss. 2, pp. 113-125
Open Access | Times Cited: 3
Lakshminarayanan Varadhan, Ponnusamy Saravanan, Sarah Ali, et al.
Clinical Drug Investigation (2022) Vol. 42, Iss. 2, pp. 113-125
Open Access | Times Cited: 3
Detección de Nuevas Tecnologías Sanitarias Para Mejorar el Control Metabólico de Pacientes Con Diabetes Tipo 2 Atendidos en el Programa de Salud Cardiovascular de Chile
Mauricio Baeza, Gustavo Sáenz‐Ravello, Cristóbal Cuadrado
Value in Health Regional Issues (2022) Vol. 31, pp. 81-92
Open Access | Times Cited: 3
Mauricio Baeza, Gustavo Sáenz‐Ravello, Cristóbal Cuadrado
Value in Health Regional Issues (2022) Vol. 31, pp. 81-92
Open Access | Times Cited: 3
Mesenchymal stromal cell therapy compared to SGLT2-inhibitors and usual care in treating diabetic kidney disease: A cost-effectiveness analysis
Luke E. Barry, Grainne Crealey, Paul Cockwell, et al.
PLoS ONE (2022) Vol. 17, Iss. 11, pp. e0274136-e0274136
Open Access | Times Cited: 3
Luke E. Barry, Grainne Crealey, Paul Cockwell, et al.
PLoS ONE (2022) Vol. 17, Iss. 11, pp. e0274136-e0274136
Open Access | Times Cited: 3
Benchmarking the medication efficiency and technological progress of diabetes drugs
Hongwei Zhang, Chen Wang, Ting Xu, et al.
Frontiers in Public Health (2024) Vol. 12
Open Access
Hongwei Zhang, Chen Wang, Ting Xu, et al.
Frontiers in Public Health (2024) Vol. 12
Open Access
Healthcare resource utilization and healthcare costs in patients with type 2 diabetes mellitus initiating sodium‐glucose cotransporter 2 inhibitors vs dipeptidyl peptidase‐4 inhibitors in Japan: A real‐world administrative database analysis
Atsunori Kashiwagi, Shingo Shoji, Yoshinori Kosakai, et al.
Journal of Diabetes Investigation (2023) Vol. 15, Iss. 3, pp. 374-387
Open Access | Times Cited: 1
Atsunori Kashiwagi, Shingo Shoji, Yoshinori Kosakai, et al.
Journal of Diabetes Investigation (2023) Vol. 15, Iss. 3, pp. 374-387
Open Access | Times Cited: 1
Clinical and Economic Rationale for the Early use of SGLT2 Inhibitors in Patients with Type 2 Diabetes
Edoardo Mannucci, P.P. Mangia, Lorenzo Pradelli
Farmeconomia Health economics and therapeutic pathways (2020) Vol. 21, Iss. 1S
Open Access | Times Cited: 1
Edoardo Mannucci, P.P. Mangia, Lorenzo Pradelli
Farmeconomia Health economics and therapeutic pathways (2020) Vol. 21, Iss. 1S
Open Access | Times Cited: 1
